Cargando…

The relationship of CDK18 expression in breast cancer to clinicopathological parameters and therapeutic response

BACKGROUND: Cyclin-Dependent Kinases (CDKs) are established anti-cancer drug targets and a new generation of CDK inhibitors are providing clinical benefits to a sub-set of breast cancer patients. We have recently shown that human CDK18 promotes efficient cellular responses to replication stress. In...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barone, Giancarlo, Arora, Arvind, Ganesh, Anil, Abdel-Fatah, Tarek, Moseley, Paul, Ali, Reem, Chan, Stephen YT, Savva, Constantinos, Schiavone, Kristina, Carmell, Natasha, Myers, Katie N., Rakha, Emad A., Madhusudan, Srinivasan, Collis, Spencer J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047673/ https://www.ncbi.nlm.nih.gov/pubmed/30034634 http://dx.doi.org/10.18632/oncotarget.25686

Ejemplares similares

Clinicopathological Significance of ATM-Chk2 Expression in Sporadic Breast Cancers: a Comprehensive Analysis in Large Cohorts()
por: Abdel-Fatah, Tarek M.A., et al.
Publicado: (2014)

Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers
por: Savva, Constantinos, et al.
Publicado: (2019)

DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers
por: Abdel-Fatah, Tarek M.A., et al.
Publicado: (2015)

Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy
por: Al-Subhi, Nouf, et al.
Publicado: (2018)

ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers
por: Abdel-Fatah, Tarek M. A., et al.
Publicado: (2019)

Is There a Role for Base Excision Repair in Estrogen/Estrogen Receptor-Driven Breast Cancers?
por: Abdel-Fatah, Tarek M.A., et al.
Publicado: (2014)

Clinicopathological and Functional Evaluation Reveal NBS1 as a Predictor of Platinum Resistance in Epithelial Ovarian Cancers
por: Alblihy, Adel, et al.
Publicado: (2021)

Untangling the clinicopathological significance of MRE11-RAD50-NBS1 complex in sporadic breast cancers
por: Alblihy, Adel, et al.
Publicado: (2021)

Human CDK18 promotes replication stress signaling and genome stability
por: Barone, Giancarlo, et al.
Publicado: (2016)

Molecular disruption of DNA polymerase β for platinum sensitisation and synthetic lethality in epithelial ovarian cancers
por: Ali, Reem, et al.
Publicado: (2021)

Ligase 1 is a predictor of platinum resistance and its blockade is synthetically lethal in XRCC1 deficient epithelial ovarian cancers
por: Ali, Reem, et al.
Publicado: (2021)

ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers
por: Abdel-Fatah, Tarek M.A., et al.
Publicado: (2014)

Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase Inhibition Is Synthetically Lethal in XRCC1 Deficient Ovarian Cancer Cells
por: Sultana, Rebeka, et al.
Publicado: (2013)

ATM Regulated PTEN Degradation Is XIAP E3 Ubiquitin Ligase Mediated in p85α Deficient Cancer Cells and Influence Platinum Sensitivity
por: Ali, Reem, et al.
Publicado: (2019)

XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib
por: Ali, Reem, et al.
Publicado: (2020)

Unravelling the clinicopathological and functional significance of replication protein A (RPA) heterotrimeric complex in breast cancers
por: Algethami, Mashael, et al.
Publicado: (2023)

The bornavirus-derived human protein EBLN1 promotes efficient cell cycle transit, microtubule organisation and genome stability
por: Myers, Katie N., et al.
Publicado: (2016)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

The frequency and clinical significance of DNA polymerase beta (POLβ) expression in breast ductal carcinoma in situ (DCIS)
por: Al-Kawaz, Abdulbaqi, et al.
Publicado: (2021)

Evolving DNA repair synthetic lethality targets in cancer
por: Kulkarni, Sanat, et al.
Publicado: (2022)

Phosphorylation of HIV-1 Tat by CDK2 in HIV-1 transcription
por: Ammosova, Tatyana, et al.
Publicado: (2006)

Identification and Validation of ERK5 as a DNA Damage Modulating Drug Target in Glioblastoma
por: Carmell, Natasha, et al.
Publicado: (2021)

Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification
por: Powe, Desmond G, et al.
Publicado: (2009)

RAD50 deficiency is a predictor of platinum sensitivity in sporadic epithelial ovarian cancers
por: Alblihy, Adel, et al.
Publicado: (2020)

Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2021)

The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2
por: Abdel-Fatah, Tarek M.A, et al.
Publicado: (2017)

Inhibition of human immunodeficiency virus type-1 by cdk inhibitors
por: Guendel, Irene, et al.
Publicado: (2010)

Clinicopathologic Features of Acute Kidney Injury Associated With CDK4/6 Inhibitors
por: Gupta, Shruti, et al.
Publicado: (2021)

The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ
por: Al-Kawaz, Abdulbaqi, et al.
Publicado: (2021)

CDK2 Regulates HIV-1 Transcription by Phosphorylation of CDK9 on Serine 90
por: Breuer, Denitra, et al.
Publicado: (2012)

MRNIP/C5orf45 Interacts with the MRN Complex and Contributes to the DNA Damage Response
por: Staples, Christopher J., et al.
Publicado: (2016)

Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers
por: Ahmad, Dena A. J., et al.
Publicado: (2016)

FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers
por: Mesquita, Katia A., et al.
Publicado: (2021)

The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays
por: Tewari, Nilanjana, et al.
Publicado: (2013)

Towards Personalized Management of Ovarian Cancer
por: Algethami, Mashael, et al.
Publicado: (2022)

Targeting Mre11 overcomes platinum resistance and induces synthetic lethality in XRCC1 deficient epithelial ovarian cancers
por: Alblihy, Adel, et al.
Publicado: (2022)

Clinicopathological Features Related to the Efficacy of CDK4/6 Inhibitor-Based Treatments in Metastatic Breast Cancer
por: Shikanai, Ayana, et al.
Publicado: (2022)

Biological and clinical significance of PARP1 protein expression in breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Altered expression of the Cdk5 activator-like protein, Cdk5α, causes neurodegeneration, in part by accelerating the rate of aging
por: Spurrier, Joshua, et al.
Publicado: (2018)

DNA damage response inhibitors enhance tumour treating fields (TTFields) potency in glioma stem-like cells
por: Vanderlinden, Aurelie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_khl0a743md396k54ng4kleuh83